| ACC | American College of Cardiology |
| ACEP | American College of Emergency Physicians |
| ACS | Acute coronary syndrome |
| AHA | American Heart Association |
| CAD | Coronary artery disease |
| CB1 | Cannabinoid receptor type 1 |
| CB2 | Cannabinoid receptor type 2 |
| CI | Confidence interval |
| CNS | Central nervous system |
| CVD | Cardiovascular disease |
| DAPT | Dual antiplatelet therapy |
| DOR | Delta-opioid receptor |
| ECG | Electrocardiogram |
| EMS | Emergency medical services |
| ESC | European Society of Cardiology |
| HR | Hazard ratio |
| ICCU | Intensive cardiac care unit |
| KOR | Kappa-opioid receptor |
| LDL-C | Low-density lipoprotein cholesterol |
| LSD | Lysergic acid diethylamide |
| MACE | Major adverse cardiovascular events |
| MDMA | 3,4-methylenedioxymethamphetamine |
| MI | Myocardial infarction |
| MOR | Mu-opioid receptor |
| NAEMSP | National Association of EMS Physicians |
| NSTEMI | Non-ST-segment elevation myocardial infarction |
| NSTE-ACS | Non-ST-elevation acute coronary syndrome |
| OR | Odds ratio |
| PCI | Percutaneous coronary intervention |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 |
| P2Y12 | P2Y12 receptor |
| ROS | Reactive oxygen species |
| SCAI | Society for Cardiovascular Angiography and Interventions |
| STEMI | ST-segment elevation myocardial infarction |
| THC | Δ9-tetrahydrocannabinol |